23
Participants
Start Date
November 30, 2004
Primary Completion Date
March 31, 2010
Study Completion Date
October 31, 2010
vatalanib
Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
Neuroendocrine Clinic, Kenner
Collaborators (1)
Novartis
INDUSTRY
Louisiana State University Health Sciences Center in New Orleans
OTHER